SCHEMBL3884680

SCHEMBL3884680

O=C(O)CCc1ccc(OC2CCCCC2)c(-c2ccc3cnccc3c2)c1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 5/20 0.52
CCNC P24863 1/20 0.45
CDK8 P49336 1/20 0.45
THRA P10827 1/20 0.45
THRB P10828 1/20 0.45
IKBKB O14920 8/20 0.44
CHUK O15111 7/20 0.44
LCK P06239 2/20 0.44
ROCK1 Q13464 2/20 0.44
S1PR1 P21453 1/20 0.44
ADRB1 P08588 2/20 0.41
ADRB3 P13945 2/20 0.41
ADRB2 P07550 1/20 0.41
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
SLC22A12 Q96S37 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3883590 0.99 FFAR4 (0.53) FFAR4CCNCCDK8THRATHRB
SCHEMBL3887851 0.90 CCNC (0.49) FFAR4CCNCCDK8IKBKBCHUK
SCHEMBL3883470 0.89 CCNC (0.50) FFAR4CCNCCDK8IKBKBCHUK
SCHEMBL3883711 0.87 FFAR4 (0.57) FFAR4CCNCCDK8THRATHRB
SCHEMBL3880651 0.87 FFAR4 (0.50) FFAR4CCNCCDK8IKBKBCHUK
SCHEMBL3679192 0.86 FFAR4 (0.58) FFAR4CCNCCDK8THRATHRB
SCHEMBL3893626 0.84 IKBKB (0.43) FFAR4IKBKBCHUKLCKROCK1
SCHEMBL3884512 0.83 IKBKB (0.44) FFAR4IKBKBCHUKLCKROCK1
SCHEMBL3884902 0.83 FFAR4 (0.48) FFAR4THRATHRBROCK1S1PR1
SCHEMBL3881066 0.83 FFAR4 (0.48) FFAR4THRATHRBROCK1S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP claimed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US claimed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP claimed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US claimed
EP-1477472-B1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2009-01-14 EP disclosed
US-6867320-B2 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2005-03-15 US disclosed
EP-1477472-A1 SUBSTITUTED PHENYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2004-11-17 EP disclosed
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044258-A1 Substituted phenylalkanoic acid derivatives and use thereof PTGER1, CYSLTR1, PTGS1 FFAR4 115/4885CCNC 2174/4885CDK8 3600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.